StockData
MacroGenics Inc logo

MacroGenics Inc (MGNX) company profile

MGNXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$2.05−0.12 (-5.53%)

Close on Nov 17, 2026Market cap $130.59MP/E –Yield –

About MacroGenics

Pharmaceutical Preparations, SIC 2834

MacroGenics, Inc. is a clinical-stage biopharmaceutical company that develops antibody-based therapeutics for cancer treatment. Utilizing proprietary multi-specific platforms such as DART and TRIDENT alongside licensed antibody-drug conjugate technologies, the company designs therapeutics for solid tumors and hematologic malignancies. Its pipeline includes investigational candidates like lorigerlimab, MGC026, and MGC028. Beyond proprietary drug development, the company generates revenue and collaborative funding by out-licensing product candidates to global biopharmaceutical partners and providing contract development and manufacturing services to external clients and commercial collaborators.

The company operates a commercial-scale current good manufacturing practice (cGMP) antibody production facility situated at its headquarters in Maryland. It maintains a worldwide patent presence, holding 58 issued patents and 24 pending applications in the United States, as well as 681 issued patents and 283 pending applications across various international jurisdictions. MacroGenics also engages in strategic drug development partnerships with major international pharmaceutical enterprises, including collaborations supporting global product development and commercialization initiatives.

Summary of the business section of MacroGenics's latest annual report, written by StockData.

Company profile

Company

Legal name
MacroGenics Inc
Founded
2000
Headquarters
Rockville, MD
Address
9704 Medical Center Drive 20850
Phone
(301) 251-5172
Employees
293, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Tysons, Virginia

Stock & identifiers

Ticker
MGNX
Exchange
Nasdaq
IPO date
Oct 11, 2013
Shares outstanding
64M, Aug 8, 2026
Public float
$73.90M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
SEC CIK
1125345
CUSIP
556099109
ISIN
US5560991094
FIGI
BBG000BM2SF8
Share class FIGI
BBG001S9C8R7
LEI
5493001KJQUA83L8MH79
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Eric Blasius RisserPresident and CEO, Director77,169
Ezio BonviniSr VP, Research & CSO201,349
Jeffrey Stuart PetersSenior VP, GC, and Secretary0
Beth Ann SmithVP, Controller & Treasurer13,204
James KarrelsSVP and CFO306,368
Thomas SpitznagelSr VP, Technical Ops38,543
Stephen L. EckChief Medical Officer29,377
Emil KuriakoseDirector–
Michael VasconcellesDirector–
William K. HeidenDirector114,750
Scott KoenigDirector1,294,720
Scott Thomas JacksonDirector14,750
Jay Philip SiegelDirector14,750
Karen Jean FerranteDirector14,750
Federica F. O'BrienDirector14,750
Edward HurwitzDirector1,752,820
Meenu ChhabraDirector14,750
Margaret LiuDirector14,750
David C. StumpDirector14,750

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025
Current PEO
$2.08M$1.48M$1.19M$7–
FY2025
Former PEO
$952.96K$192.14K$1.19M$7–
FY2024
Current PEO
$0$0$2.51M$14–
FY2024
Former PEO
$6.40M$1.78M$2.51M$14–
FY2023
Current PEO
$0$0$1.66M$42–
FY2023
Former PEO
$3.71M$6.49M$1.66M$42–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsIncentive payOtherTotalvs. prior year
Eric Risser
President, Chief Executive Officer and Director
$561.57K$150.00K$52.00K$1.05M$251.90K$14.00K$2.08M–
Scott Koenig, M.D., Ph.D.
Former Chief Executive Officer and current Director
$477.12K––––$475.84K$952.96K-85%
Ezio Bonvini
Senior Vice President, Research and Chief Scientific Officer
$533.20K$150.00K$54.60K$288.04K$184.20K$14.00K$1.22M–
James Karrels
Senior Vice President and Chief Financial Officer
$506.55K$150.00K$49.40K$254.28K$175.00K$14.00K$1.15M-51%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Oct 11, 2013
Offer price
$16.00
Securities offered
5,000,000
Gross proceeds
$80.00M
Exchange
Nasdaq
First trading day
Oct 10, 2013
First-day close
$24.99+56.2%
Lock-up ends (est.)
Apr 8, 2014

“Per share Total Initial public offering price $ 16.00 $ 80,000,000 Underwriting discounts and commissions 1 $ 1.12 $ 5,600,000 Proceeds before expenses, to us $ 14.88 $ 74,400,000 1 We refer you to “Underwriting” beginning on page 158 of this prospectus for additional information regarding total underwriter compens”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of February 28, 2026, we had 293 full-time employees, 245 of whom were primarily engaged in research, development and manufacturing activities, an d 61 of whom had an M.D.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?